Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3084619rdf:typepubmed:Citationlld:pubmed
pubmed-article:3084619lifeskim:mentionsumls-concept:C1140680lld:lifeskim
pubmed-article:3084619lifeskim:mentionsumls-concept:C0331677lld:lifeskim
pubmed-article:3084619lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:3084619lifeskim:mentionsumls-concept:C0221908lld:lifeskim
pubmed-article:3084619lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:3084619lifeskim:mentionsumls-concept:C0034390lld:lifeskim
pubmed-article:3084619lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:3084619pubmed:issue1lld:pubmed
pubmed-article:3084619pubmed:dateCreated1986-6-11lld:pubmed
pubmed-article:3084619pubmed:abstractTextResults of initial chemotherapy in 143 patients with advanced epithelial ovarian cancer are presented. Twenty-five patients were treated with alkylating agents, their median survival was 13 months and 15% were alive at 4 years. Nineteen received Cyclophosphamide-Methotrexate-5 Fluorouracil with or without Hexamethylmelamine, median survival was 22 months and 4 years survival was 20%. Forty-eight were treated with Adriamycin and Cisplatinum, their objective response rate proven by second-look laparotomy was 54.4% (26.1% complete response), median survival was 23 months and 35% were alive at 4 years. Thirty-one received Hexamethylmelamine, 5 Fluorouracil, Adriamycin and Cisplatinum with a median survival of 18 months and 4 years survival of 15%. Twenty had various other chemotherapy regimens, their median survival was only 8 months. Recent advances in the therapy of ovarian carcinoma are also discussed.lld:pubmed
pubmed-article:3084619pubmed:languagefrelld:pubmed
pubmed-article:3084619pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084619pubmed:citationSubsetIMlld:pubmed
pubmed-article:3084619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084619pubmed:statusMEDLINElld:pubmed
pubmed-article:3084619pubmed:issn0368-2315lld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:KrulikMMlld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:BlouinRRlld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:LavoieAAlld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:DrayCClld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:de GramontAAlld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:LouvetCClld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:PignéAAlld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:TessierCClld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:DroletYYlld:pubmed
pubmed-article:3084619pubmed:authorpubmed-author:PainchaudMMlld:pubmed
pubmed-article:3084619pubmed:issnTypePrintlld:pubmed
pubmed-article:3084619pubmed:volume15lld:pubmed
pubmed-article:3084619pubmed:ownerNLMlld:pubmed
pubmed-article:3084619pubmed:authorsCompleteNlld:pubmed
pubmed-article:3084619pubmed:pagination105-9lld:pubmed
pubmed-article:3084619pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:meshHeadingpubmed-meshheading:3084619-...lld:pubmed
pubmed-article:3084619pubmed:year1986lld:pubmed
pubmed-article:3084619pubmed:articleTitle[Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].lld:pubmed
pubmed-article:3084619pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3084619pubmed:publicationTypeEnglish Abstractlld:pubmed